Akorn Inc. Names Douglas R. Pinnell As Vice President, Vaccine Sales.

BUFFALO GROVE, Ill. -- Akorn, Inc. (NASDAQ:AKRX) today announced the appointment of Douglas R. Pinnell as Vice President, Vaccine Sales. Mr. Pinnell brings over fifteen years experience in vaccine sales and marketing, including substantial experience in building and leading pharmaceutical sales organizations.

Prior to joining Akorn, from 2005 to 2007 Mr. Pinnell served as Executive Sales and Marketing Consultant at NABI Biopharmaceuticals, Boca Raton, FL where his primary objective was to establish a sales and marketing campaign for new vaccines and biological products under clinical development. From 2003 to 2005, Mr. Pinnell served as Vice President of Sales for Chiron Vaccines, where he directed sales operations for North America for Chiron's influenza, meningitis and rabies vaccine products.

Mr. Pinnell served as Executive Vice President, Sales and Marketing for Powderject Pharmaceuticals, Oxford England, from 2000 through 2003. At Powderject he directed the re-launch of Powderject's influenza vaccine for the U.S. market. From 1995 through 1999, he served as Director of Sales for North American Vaccine, Inc., Beltsville, MD where he managed the product launches of several biotechnology-developed vaccines.

Arthur S. Przybyl, president and chief executive officer, stated, "We are excited to have Doug join our senior management team. He brings substantial leadership experience in the vaccine market and will have full responsibility for our third quarter diphtheria- tetanus vaccine launch."

About Akorn, Inc.

Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey and markets and distributes an extensive line of hospital and ophthalmic pharmaceuticals. Additional information is available at the Company's website at www.akorn.com.

Materials in this press release may contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements give our expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to future steps we may take, prospective products, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results.

Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed. Our actual results may vary materially, and there are not guarantees about the performance of our stock.

Any forward-looking statements represent our expectations or forecasts only as of the date they were made and should not be relied upon as representing our expectations or forecasts as of any subsequent date. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise, even if our expectations or forecasts change. You are advised, however, to consult any further disclosures we make on related subjects in our reports filed with the SEC. In particular, you should read the discussion in the section entitled "Cautionary Statement Regarding Forward-Looking Statements" in our most recent Annual Report on Form 10-K, as it may be updated in subsequent reports filed with the SEC. That discussion covers certain risks, uncertainties and possibly inaccurate assumptions that could cause our actual results to differ materially from expected and historical results. Such factors include, but are not limited to, risks and uncertainties relating to the resolution of the FDA compliance issues at our Decatur, Illinois manufacturing facility. Other factors besides those listed there could also adversely affect our results.